Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.

Lima L, Bernal-Mizrachi L, Saxe D, Mann KP, Tighiouart M, Arellano M, Heffner L, McLemore M, Langston A, Winton E, Khoury HJ.

Cancer. 2011 Mar 15;117(6):1245-52. doi: 10.1002/cncr.25678. Epub 2010 Nov 2.

2.

Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.

Takahashi N, Miura I, Kobayashi Y, Kume M, Yoshioka T, Otane W, Ohtsubo K, Takahashi K, Kitabayashi A, Kawabata Y, Hirokawa M, Nishijima H, Ichinohasama R, Decoteau J, Miura AB, Sawada K.

Int J Hematol. 2005 Apr;81(3):235-41.

PMID:
15814334
3.

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW.

Haematologica. 2004 Jan;89(1):49-57.

4.
5.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
6.

[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].

Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.

Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):1-5. Chinese.

PMID:
15946498
7.

Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.

Kolb EA, Pan Q, Ladanyi M, Steinherz PG.

Cancer. 2003 Dec 15;98(12):2643-50. Review.

8.

[Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].

Chelysheva EIu, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND.

Ter Arkh. 2007;79(4):49-53. Russian.

PMID:
17564019
10.

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.

Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC.

Am J Clin Pathol. 2003 Jun;119(6):833-41.

PMID:
12817431
11.

Monitoring disease response to tyrosine kinase inhibitor therapy in CML.

Hughes TP, Branford S.

Hematology Am Soc Hematol Educ Program. 2009:477-87. doi: 10.1182/asheducation-2009.1.477. Review.

PMID:
20008233
12.

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K.

J Assoc Physicians India. 2007 Feb;55:109-13.

PMID:
17571739
13.

The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.

Jiang Q, Zhao XY, Qin YZ, Liu YR, Lai YY, Jiang B, Huang XJ.

Am J Hematol. 2012 Dec;87(12):1065-9. doi: 10.1002/ajh.23321. Epub 2012 Sep 11.

14.

Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.

Fugazza G, Miglino M, Bruzzone R, Quintino S, Gatti AM, Grasso R, Gobbi M, Frassoni F, Sessarego M.

J Exp Clin Cancer Res. 2004 Jun;23(2):295-9.

PMID:
15354415
15.

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.

Akard LP, Cortes JE, Albitar M, Goldberg SL, Warsi G, Wetzler M, Ericson SG, Radich JP.

Arch Pathol Lab Med. 2014 Sep;138(9):1186-92. doi: 10.5858/arpa.2013-0584-OA. Epub 2013 Dec 5.

PMID:
24308645
16.

Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.

Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.

Ann Hematol. 2006 Dec;85(12):841-7. Epub 2006 Sep 28.

PMID:
17006667
17.
18.

[The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].

Miyanishi S, Umeki K, Hayashi T, Fukutsuka K, Okumura A, Kishimori C.

Rinsho Byori. 2003 Oct;51(10):1023-9. Japanese.

PMID:
14653203
19.

Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.

Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I, Carturan S, Messa E, Morotti A, Giugliano E, Rege-Cambrin G, Alberti D, Baccarani M, Saglio G.

Cancer. 2004 Sep 1;101(5):979-88.

20.

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ.

Blood. 2003 Jun 15;101(12):4701-7. Epub 2003 Feb 6.

Supplemental Content

Support Center